PARP Inhibitor–Based Combinations to Improve Patient Outcomes in Prostate Cancer: An Evidence-Based Global Perspective

Review expert insights on PARP inhibitor combination approaches including combinations with AR-directed therapy and immune checkpoint inhibitors.

Charles J. Ryan, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: April 12, 2021 Expired: No longer available for credit

Here are my thoughts on some of the ongoing clinical trials of combination therapy approaches using PARP inhibitors in advanced prostate cancer.

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: January 25, 2021

前立腺進行がんにおいてRARP阻害薬を使用した組み合わせ療法のアプローチの現在進行中の治験に関する自分の考え。

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

Voici mes réflexions sur certains des essais cliniques en cours portant sur des associations thérapeutiques utilisant des inhibiteurs de la PARP dans le traitement du cancer avancé de la prostate.

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: February 25, 2021

Hier sind meine Überlegungen zu einigen laufenden klinischen Studien zu Kombinationstherapieansätzen mit PARP-Inhibitoren bei fortgeschrittenem Prostatakrebs.

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

Questa è la mia opinione su alcune sperimentazioni cliniche in corso sugli approcci con terapia combinata, utilizzando gli inibitori PARP, nel cancro alla prostata avanzato.

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

Estas son mis consideraciones sobre algunos de los ensayos clínicos en curso de enfoques de terapia combinada que utilizan inhibidores de PARP en el cáncer de próstata avanzado.

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: February 25, 2021

In this podcast episode, listen to medical oncologists Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the rationale for using PARP inhibitors in combination with other therapies for prostate cancer.

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 15, 2021

Download this slideset to learn more about the rationale for combining PARP inhibitors with a variety of agents including androgen receptor directed therapy, immune checkpoint inhibitors, and DNA damaging agents as discussed in our podcast.

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 16, 2021

In this podcast episode, listen to medical oncologists Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the latest results from ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostatic cancer.

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 19, 2021

Download this slideset to learn more about the clinical trials discussed in our podcast focused on PARP inhibitor combination approaches to broaden the utility of PARP inhibition in prostate cancer.

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 19, 2021

Download this slideset for expert insight on the latest evidence on PARP inhibition and novel PARP inhibitor combination therapy in advanced prostate cancer.

Charles J. Ryan, MD Released: April 12, 2021